Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

RedCloud Doses NSCLC Patient in China Trial of Next-Gen EGFR TK

publication date: Aug 29, 2022

Shanghai RedCloud Bio dosed the first patient in a China Phase I/II trial of its lead product, a next-gen EGFR TKI candidate for NSCLC with the C797S mutation that is resistant to other EGFR TKIS therapies. RedCloud uses structural pharmacology and computational approaches for small molecule drug discovery and development. H002 is a fourth-gen EGRF inhibitor discovered by RedCloud. In preclinical studies, the candidate showed broad-spectrum potency and high selectivity against EGFR mutations, including single, double and triple mutations. H0002 has also shown potent anti-tumor activity in an EGFR-positive brain metastases model. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022